Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.

NEW YORK, Feb. 13 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an updated Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc. (BNC: TSX). The full 68-page report can be found at

Bioniche Life Sciences Inc. ("Bioniche" or "the Company") is a Canadian biopharmaceutical company that aims to improve the quality of life in both humans and animals through innovative research, technologies, and therapeutics. To develop the proprietary platform technologies that the Company uses to create human and animal therapeutic agents, Bioniche is structured in three global business units: (1) Bioniche Therapeutics (Human Health); (2) Bioniche Animal Health; and (3) Bioniche Food Safety.

The Company's most advanced Human Health product candidate is Urocidin(TM), a treatment for non-muscle-invasive bladder cancer that entered Phase III clinical development in late 2006 after the U.S. Food and Drug Administration (FDA) granted Bioniche Fast Track status. A second Phase III trial is likely to begin under the FDA's Special Protocol Assessment (SPA) and Fast Track designations after the current Phase III trial is fully enrolled and when financing is available.

Bioniche Animal Health markets over 100 products globally, developing products that enhance reproductive performance in animals and reduce the animal health industry's reliance on antibiotics. With fiscal 2008 revenues of C$17.5 million, the line of reproductive products comprises Bioniche Animal Health's largest sales category. As a whole, the business unit had fiscal 2008 revenues of C$27.7 million. A lead Animal Health product is Folltropin(R)-V, a reproductive hormone that induces superovulation in cattle and sheep.

Bioniche Food Safety develops veterinary biopharmaceuticals to improve the safety of human food and water supplies. Its most significant initiative is Econiche(TM), a vaccine administered to cattle that reduces the level of Escherichia coli (E. coli) O157:H7 that cattle shed, thus minimizing the risk of human illness from contaminated food or water. The vaccine was fully licensed in Canada in October 2008. In addition, in mid-2008, the Company secured C$25 million in government funding for a vaccine production facility scale-up in Belleville, Ontario, Canada, as part of a long-term C$107 million project to create an Animal Health and Food Safety Vaccine Manufacturing Centre.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of sixty-two thousand five hundred U.S. dollars and one hundred fifty thousand Options/Warrants for its services in creating and updating the base report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with SEDAR.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.

SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Recombinant Human Renin - Crystallographic Grade
2. 3-D photonic crystals will revolutionize telecommunications
3. Researchers outline structure of largest nonvirus particle ever crystallized
4. DNA technique yields 3-D crystalline organization of nanoparticles
5. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
6. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
7. NC State breakthrough results in super-hard nanocrystalline iron that can take the heat
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
9. Silicon photonic crystals key to optical cloaking, researchers say
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):